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Abstract
Background: Identifying the subset of patients with clinically localized prostate cancer (PCa) at the highest risk of
recurrence remains challenging, and better prognostic markers are needed. Gleason score is the best predictor of
PCa aggressiveness and prognosis. In the present study, we generated an epigenetic signature based on high
versus low Gleason score tumors and evaluated its ability to predict recurrence after radical prostatectomy.
Methods: Genome-wide DNA methylation data from The Cancer Genome Atlas (TCGA; no. of patients = 333) and
the elastic net method were used to generate an epigenetic signature by contrasting patients with high (8–10)
versus low (≤6) Gleason score tumors. The signature was then tested in a cohort of 523 patients with clinically
localized disease who had radical prostatectomy. Samples taken from the primary tumor were used for DNA
methylation and mRNA expression profiling. Patients were followed for PCa recurrence on average for 8 years
after diagnosis.
Results: The epigenetic signature includes 52 differentially methylated CpG sites. In the testing cohort, the
signature was associated with poorer recurrence-free survival (hazard ratio per 25 % increase = 1.78; 95 %
confidence interval 1.48, 2.16). The signature significantly improved the area under the curve (AUC) for PCa
recurrence compared to clinical-pathological parameters alone, particularly among patients diagnosed with
Gleason score 7 tumors (0.64 vs. 0.76, P = 1.34E−4). Results were comparable for patients with Gleason 3 + 4 and
those with 4 + 3 tumors. Gene Set Enrichment Analysis showed that higher levels of the signature were
associated with increased expression of genes related to cell cycle proliferation and decreased expression of
androgen-responsive genes.
Conclusions: This report shows evidence that DNA methylation patterns measured in prostate tumor cells are
predictive of PCa aggressiveness. The epigenetic signature may have clinical utility to improve prognostication
particularly in patients with intermediate Gleason score 7 tumors.
Keywords: Clinically localized prostate cancer, Tumor tissue, DNA methylation, Gene expression, Risk prediction
for prognosis, Genome-wide profiling, Elastic net regularization
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Background
Prostate cancer (PCa) is the most common solid tumor
in men [1]. While many PCa patients are diagnosed with
indolent disease that is unlikely to progress even if left
untreated, other patients will have aggressive tumors
that may become life-threatening [2–4]. Although current
clinical and pathological measures such as Gleason score
(tumor grade), disease stage, and prostate-specific antigen
(PSA) level provide important prognostic information,
they do not accurately predict an individual patient's
risk of progression, and better markers to aid prognos-
tication are needed [4, 5].
DNA methylation is an epigenetic alteration that oc-
curs at CG dinucleotides (CpG sites) [6]. The human
DNA methylome is generated in a programmed manner
during normal development and methylation patterns
change as a result of aging [7]. Patterns of DNA methy-
lation record a remarkable breadth of information about
cells, including their chronological age, developmental
history, and differentiation potential [8, 9]. In PCa, there
is substantial heterogeneity in tumor DNA methylation
profiles [10], and these epigenetic changes may also pre-
dict PCa aggressiveness. Some previous studies showed
that differentially methylated CpG sites in specific genes
are associated with more aggressive and advanced PCa,
but most of these investigations focused on selected can-
didate genes and findings require validation [11–18].
In this study, we generated an epigenetic (DNA
methylation) signature for use as a prognostic classifier
in PCa. Because Gleason score is the best predictor of
PCa prognosis [19], we generated the signature by con-
trasting patients with high (8–10) versus low (≤6)
Gleason score tumors. The signature was then tested
for its ability to predict recurrence in a validation co-




The Fred Hutchinson (FH) Cancer Research Center co-
hort includes 565 PCa patients who underwent radical
prostatectomy as primary therapy for clinically local-
ized adenocarcinoma of the prostate. These patients
were previously enrolled in population-based studies of
PCa (diagnosed in 1993–1996 or 2002–2005) [20, 21].
Clinical information and vital status were collected from
the Seattle-Puget Sound Surveillance, Epidemiology, and
End Results (SEER) Program cancer registry. Prostate can-
cer recurrence status was determined from two detailed
follow-up surveys that were completed by patients in
2004–2005 and in 2010–2011, with review of medical re-
cords or physician follow-up as needed. A patient was
considered to have disease recurrence based on (1) a post-
surgery PSA value of 0.2 ng/mL or greater; (2) metastatic
progression on a bone scan, MRI, CT, or biopsy; and (3)
PCa-specific death. The mean follow-up time for recur-
rence was 8 years. The Institutional Review Board of the
Fred Hutchinson Cancer Research Center approved the
study, and all participants signed informed consent
statements.
DNA and RNA isolation
Formalin-fixed paraffin-embedded (FFPE) prostate tumor
tissue blocks were obtained from radical prostatectomy
specimens and used to make hematoxylin and eosin-
stained slides, which were reviewed by a PCa pathologist
to confirm the presence and location of prostate adeno-
carcinoma. For each patient, two 1-mm tumor tissue cores
from the dominant lesion that were enriched with ≥75 %
tumor cells were taken for DNA and RNA purification.
The RecoverAll Total Nucleic Acid Isolation Kit (Ambion,
Applied Biosciences, Austin, TX) was used to extract
DNA. The RNeasy® FFPE Kit (Qiagen Inc., Valencia, CA)
was used to isolate RNA. DNA and RNA samples were
shipped to Illumina (Illumina, Inc., San Diego, CA) for
DNA methylation and mRNA expression profiling.
Molecular profiling and data preprocessing
Tumor DNA was bisulfite converted. The Infinium®
HumanMethylation450 BeadChip array (Illumina) was
used for methylation profiling. Methylation data were nor-
malized using subset-quantile within array normalization
(minfi in Bioconductor) [22], and batch effects were re-
moved using ComBat [23]. Methylation β values were cal-
culated, which represent the percentage of DNA
methylation at a CpG site. Genome annotation was based
on the Illumina Manifest, and a gene promoter region was
defined as TSS1500, TSS200, 5′UTR, or 1stExon. Across
the 96-well plates, we incorporated blind duplicate (n =
16) and replicate (n = 2) samples. A sample was excluded
if less than 95 % of the CpG sites for that sample on the
array were detected with a detection P value (probability
of a CpG being detected above the background level de-
fined by negative control probes) of <0.05, and 42 samples
were excluded. Further, CpG sites with a detection P value
of >0.01 were excluded. Correlation coefficients for dupli-
cate samples were 0.96–0.99. The correlation coefficient
for the replicate samples was 0.99. There were 523 pa-
tients with DNA methylation data.
The HumanHT-12 v4.0 Whole-Genome DASL HT
Assay (Illumina) was used for gene expression profil-
ing. Low-quality probes were filtered out (illuminaHu-
manWGDASLv4.db package in Bioconductor). Gene
expression data were quantile normalized and log2
transformed. Batch effects were removed using Com-
Bat [23]. Genome annotation was based on the Illu-
mina protocol. Blind duplicate samples from 11
patients had correlations ranging from 0.98 to 0.99,
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and replicate samples from two patients had mean cor-
relations of 0.99. There were 469 patients with mRNA
expression data, and these patients also had DNA
methylation data.
The Cancer Genome Atlas DNA methylation data
Level 1 Infinium HumanMethylation450 data were
downloaded from The Cancer Genome Atlas (TCGA)
data portal (https://tcga-data.nci.nih.gov/tcga/). The
TCGA dataset includes 333 PCa patients who received
radical prostatectomy [10]. The number of patients with
Gleason ≤6, 7(3 + 4), 7(4 + 3), and 8–10 tumors is 65,
102, 78, and 88, respectively. Data on long-term patient
outcomes are not available in TCGA [10]. Gene expres-
sion data from TCGA were downloaded from the Can-
cer Browser (https://genome-cancer.ucsc.edu/).
Statistical data analysis
Genome-wide DNA methylation data from TCGA were
used to generate an epigenetic signature of Gleason
score by contrasting patients with high (8–10) versus
low (≤6) Gleason score tumors. The signature was built
using the elastic net method (glmnet in R), which is a
regularization and variable selection method for high-
dimensional data [24]. This approach is a combination
of traditional LASSO and ridge regression methods, em-
phasizing model sparsity while appropriately balancing
the contributions of correlated variables [25]. All CpG
sites were used as input for the analysis. Fivefold
cross-validation and the area under the curve (AUC)
criterion were used to determine the optimal tuning
parameter λ for classification. After variable selection
using elastic net, the signature was calculated as fol-
lows: signaturei = ∑g = 1
n βg×Xgi, where g is the marker
(i.e., CpG site); n is the number of markers; βg is the
elastic net coefficient for marker g; and Xgi is the
methylation value for marker g and patient i.
The epigenetic signature was next evaluated for its
ability to predict PCa recurrence in the FH cohort.
Kaplan-Maier analysis and Cox regression models were
used to examine the association between quartiles of the
signature and recurrence-free survival. Hazard ratios
(HRs) and 95 % confidence intervals (CIs) were calcu-
lated. A receiver operating characteristic (ROC) analysis
was performed to evaluate the ability of the signature to
distinguish patients with no evidence of recurrence
from those who developed recurrence. A likelihood ra-
tio test was used to compare a model that included the
standard clinical-pathological parameters Gleason score
(≤6, 7(3 + 4), 7(4 + 3), and 8–10), pathological stage
(local: pT2, N0/NX, M0; regional: pT3-T4 and/or N1,
M0), and diagnostic PSA level (1-unit increase), with a
model that included these clinical-pathological vari-
ables and the epigenetic signature.
Tumor mRNA expression data were then used to
study correlations between methylation levels of individ-
ual CpG sites in the signature and expression levels of
corresponding genes. Pearson correlation coefficients
were used. Next, Gene Set Enrichment Analysis (GSEA)
was performed [26]. First, correlations between the sig-
nature and genome-wide gene expression levels were
evaluated. The genes were then pre-ranked according to
Pearson correlation and false discovery rate (FDR) Q
value. Genes with a Q value of <0.05 were used as input
for GSEA. For those genes with multiple transcripts, the
average mean correlation across transcripts was calcu-
lated. GSEA was run with 1000 gene set permutations to
calculate FDR Q values. We tested for the enrichment of
“hallmark” gene sets, which have been shown to reduce
variation and redundancy thereby providing more re-
fined and concise inputs for GSEA [27]. The GSEA re-
sults were shown using normalized enrichment scores
(NES), which is a value assigned to each gene set after
normalization across all analyzed gene sets. NES is cal-
culated by the following formula: NES = actual ES/mean
(ESs against all permutations of the dataset) [26, 28]. All
statistical analyses were done using R.
Results
The epigenetic signature of Gleason score generated in
the TCGA cohort includes 52 differentially methylated
CpG sites (Fig. 1a, b). Patients with Gleason score 7 tu-
mors had intermediate levels of the signature compared
to Gleason ≤6 and 8–10 tumors (Fig. 1c). Twenty-one
CpGs in the signature had higher methylation levels in
Gleason 8–10 tumors (Table 1). Thirty-six CpGs are in
genes (32 unique genes), and 18 are in gene promoter
regions. In the FH cohort (Table 2), higher levels of the
signature correlated with increasing Gleason score (correl-
ation = 0.33; P = 2.11E−14) (Additional file 1: Figure S1).
The epigenetic signature was then tested for its ability
to predict recurrence in the FH cohort. Higher levels of
the signature were associated with poorer recurrence-
free survival (Fig. 2a). The 5- and 10-year risk of recur-
rence increased with increasing quartiles of the signa-
ture: 8, 9, 14, and 27 % and 11, 20, 32, and 44 %,
respectively. The HR of recurrence for each 25 % incre-
ment in the signature was 1.78 (95 % CI 1.48, 2.16),
which remained significant after adjusting for Gleason
score, pathological stage, and diagnostic PSA level
(Table 3). Adding the signature to a model that included
these prognostic parameters significantly improved the
AUC for recurrence (0.73 vs. 0.78, P = 2.72E−5; Fig 2b).
In this study, 24 patients with no recurrence and 17 pa-
tients with recurrence had adjuvant therapy after radical
prostatectomy. Excluding these 41 patients did not sub-
stantially change the signature’s association with recur-
rence (HR per 25 % increase 1.81; 95 % CI 1.49, 2.20).
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Fig. 1 Epigenetic signature of Gleason score in The Cancer Genome Atlas. a Variable selection using elastic net. Each curve in the figure corresponds
to a single CpG site. It shows the path of its coefficient (y-axis) against the log(lambda) or tuning parameter (x-axis). The vertical dashed line represents
the optimal log(lambda) for classifying high (8−10) versus low (≤6) Gleason score tumors, which was identified using cross-validation. Based on an
optimal log(lambda) of −1.7061, 52 CpG sites were selected. These 52 CpGs and their elastic net coefficients were then used to calculate the epigenetic
signature as described in the “Methods” section. b Heatmap of the 52 CpG sites that were selected using elastic net. The rows of the heatmap are the
CpG sites, and the columns are the tumor samples. The samples were grouped by Gleason score. Methylation β values (range 0−1) were used, and the
highest methylation levels are shown in red. The number of patients with Gleason ≤6, 7(3 + 4), 7(4 + 3), and 8−10 tumors is 65, 102, 78, and 88,
respectively. The rows were clustered based on Euclidean distance. c Box plots of the epigenetic signature (y-axis) for patients with different Gleason
scores. The signature is presented as a proportion. Higher Gleason scores were associated with higher levels of the signature. The same patients as in
Fig. 1b were used
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Table 1 Fifty-two CpG sites included in the epigenetic signature




Mean β difference Elastic Net
coefficient
cg10145000 1 0.44 0.31 0.12 −0.0043
cg00043324 1 0.87 0.90 0.03 0.2022
cg00506866 2 RRM2 Body Island 0.16 0.11 0.04 −0.2591
cg02601249 2 S_Shore 0.80 0.62 0.17 −0.1426
cg15454811 2 0.82 0.65 0.17 −0.1904
cg09741917 2 VWA3B TSS1500 N_Shore 0.49 0.63 0.14 0.3933
cg13607230 2 MFSD9 Body N_Shore 0.43 0.56 0.13 0.5376
cg17353895 2 ANO7 3'UTR;Body 0.65 0.76 0.10 0.5339
cg05287437 3 GALNTL2 TSS1500 0.77 0.63 0.14 −1.5620
cg13333267 3 SEMA3F 5'UTR S_Shelf 0.48 0.59 0.11 0.0180
cg13320202 3 ATXN7 Body S_Shore 0.48 0.36 0.12 −0.0575
cg10523671 3 SLC15A2 TSS1500 0.45 0.62 0.17 0.3300
cg02034887 3 SLC15A2 TSS200 0.27 0.40 0.14 0.0982
cg05962239 3 MME 5'UTR;1stExon S_Shore 0.24 0.14 0.10 −0.2355
cg27473997 4 USP17 TSS200 0.71 0.55 0.17 −0.2529
cg13432241 4 KIAA0922 Body S_Shore 0.61 0.44 0.17 −0.4088
cg08415137 5 0.13 0.09 0.04 −0.0529
cg01106114 5 FOXI1 TSS1500 N_Shore 0.41 0.52 0.11 0.0330
cg20997710 7 0.47 0.30 0.17 −0.2326
cg03490567 7 URGCP 5'UTR;Body N_Shore 0.23 0.34 0.10 0.0660
cg10218605 7 PTPRN2 Body N_Shore 0.30 0.50 0.20 0.0037
cg00201595 8 0.82 0.78 0.04 −0.3187
cg08092111 8 RP1 Body S_Shore 0.72 0.57 0.16 −0.0906
cg26598831 8 0.63 0.42 0.21 −0.1777
cg06728098 8 MRPS28 Body N_Shore 0.12 0.10 0.02 −0.4359
cg17929627 10 MKI67 5'UTR Island 0.17 0.11 0.06 −2.2937
cg23656300 10 0.71 0.55 0.16 −0.0168
cg20809737 11 CPT1A Body 0.78 0.70 0.09 −0.7679
cg05280814 11 N_Shelf 0.55 0.73 0.18 0.8970
cg15401862 12 KCNMB4 3'UTR 0.87 0.80 0.07 −0.2301
cg02767665 12 TMEM132D Body S_Shore 0.63 0.45 0.18 −0.3594
cg22795345 13 ARHGEF7 Body Island 0.35 0.64 0.29 0.2448
cg14270002 13 ARHGEF7 Body Island 0.28 0.57 0.29 0.2159
cg24743156 14 CTAGE5 TSS1500;Body N_Shore 0.32 0.43 0.11 0.0997
cg25407064 15 EIF2AK4 TSS200 Island 0.04 0.03 0.01 −1.5429
cg12921171 15 0.53 0.65 0.12 0.5505
cg18054026 15 C15orf26 Body S_Shore 0.42 0.53 0.12 0.1548
cg11470399 16 PLK1 1stExon Island 0.14 0.11 0.03 −1.5771
cg04138181 16 PLK1 Body S_Shore 0.25 0.15 0.10 −1.1582
cg27106909 16 YPEL3 1stExon;5'UTR N_Shore 0.20 0.37 0.17 0.2890
cg06285575 16 ZNF267 Body S_Shelf 0.21 0.33 0.12 0.0053
cg09848947 16 FAM38A Body 0.77 0.66 0.11 −0.4029
cg06751612 16 FAM38A Body 0.86 0.76 0.11 −0.5474
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Patients diagnosed with Gleason score 7 tumors repre-
sent a large and clinically heterogeneous subgroup of pa-
tients with a variable prognosis [19, 29]. In this study,
Gleason 7 patients with the highest levels of the signa-
ture had lower recurrence-free survival rates (Fig. 2c;
Table 3). Adding the signature to a model with trad-
itional clinical-pathological parameters improved the
AUC for recurrence (0.64 vs. 0.76, P = 1.34E−4; Fig. 2d).
The majority of patients with Gleason score 7 tumors
had Gleason 3 + 4, which is considered less aggressive
compared to Gleason 4 + 3 [19]. In the subset of patients
with Gleason 7(3 + 4) tumors, the signature was associ-
ated with a higher risk of recurrence (Fig. 2e; Table 3)
and significantly improved the AUC for recurrence (0.59
vs. 0.76, P = 2.12E−4; Fig 2f ). Although there were few
patients with Gleason 7(4 + 3) tumors in the testing
dataset, the signature also improved the AUC for recur-
rence in this subgroup (0.62 vs. 0.70; P = 0.14).
For 14 of the genes that encompass CpGs in the signa-
ture, DNA methylation levels were associated with mRNA
expression levels of the corresponding genes in the FH co-
hort (P < 0.05; Additional file 2: Table S1). For three genes,
there was an (modest) inverse correlation between methyla-
tion levels of CpGs in gene promoter regions and mRNA
expression levels. Three other genes had stronger correla-
tions of higher methylation and lower expression levels
(correlation < −0.2): ANO7, ARHGEF7, and PTPRN2. The
CpG sites in these genes were in the gene body or 3′UTR
region. Analysis of TCGA data provided confirmatory
evidence for these findings (Additional file 2: Table S1).
Correlations between the signature and genome-wide
gene expression levels were then evaluated in the FH
cohort. We identified 1266 significantly upregulated
transcripts (FDR Q value < 0.05), which involved 1108
unique genes, and 1673 downregulated transcripts, which
involved 1357 unique genes (Additional file 3: Table S2).
The genes were used as input for GSEA (Table 4). The
analysis showed that the upregulated genes in our study
(positive NES) were enriched for gene sets related to
cell cycle proliferation (i.e., HALLMARK_E2F_TARGETS,
HALLMARK_G2M_CHECKPOINT,HALLMARK_MITO-
TIC_SPINDLE, and HALLMARK_MYC_TARGETS_V1).
Comparing our list of genes to KEGG pathways identified
the gene set KEGG_CELL_CYCLE as the top-ranked gene
set (NES = 2.36). Finally, we evaluated a 31-gene expression
signature of cell cycle proliferation (CCP) that was
Table 1 Fifty-two CpG sites included in the epigenetic signature (Continued)
cg10576459 17 0.89 0.79 0.10 −0.0067
cg01135464 17 0.33 0.57 0.24 0.7303
cg22438006 18 N_Shelf 0.66 0.49 0.18 −0.0625
cg07164161 18 KCNG2 Body S_Shore 0.53 0.42 0.11 −0.0296
cg09960641 19 LOC100128675 TSS1500 0.31 0.46 0.14 0.2864
cg25286393 19 NAPSA TSS1500 0.70 0.59 0.11 −0.0201
cg12551567 20 CDC25B 1stExon Island 0.10 0.08 0.02 −0.4047
cg07944494 21 Island 0.94 0.96 0.02 0.1070
cg07260325 X 0.74 0.66 0.08 −0.1695
Table 2 Selected characteristics of patients in the Fred
Hutchinson prostate cancer patient cohort
Variables Patients (n = 523)
Number Percentage (%) Mean (SD)












7(3 + 4) 188 35.9
7(4 + 3) 45 8.6
8–10 38 7.3






No recurrence 323 74.9
Recurrence 108 25.1
Follow-up time (years)b 8.0 (4.2)
PSA prostate-specific antigen
aLocal stage is pT2, N0/NX, M0. Regional stage is pT3-T4 and/or N1, M0
bTwenty-six patients had missing data on diagnostic PSA levels, and 92
patients had missing data on recurrence. Three additional patients had
missing follow-up data
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previously shown to be associated with PCa mortality
when assessed in primary tumors [30, 31]. In our study,
expression levels of 25 genes in the CCP score signifi-
cantly increased with higher levels of the epigenetic sig-
nature (FDR Q value < 0.05).
Discussion
In the present study, an epigenetic signature of Gleason
score was generated. The study showed that the signa-
ture predicted recurrence-free survival after radical
prostatectomy.
Fig. 2 Epigenetic signature of Gleason score and prostate cancer recurrence in the Fred Hutchinson cohort. a Recurrence-free survival by quartiles
(Q1–4) of the epigenetic signature. The vertical dashed line shows the recurrence-free survival rate at 10 years after diagnosis. b The signature
improved the prediction of recurrence beyond the standard clinical-pathological parameters: Gleason score, pathological stage, and diagnostic
PSA level (likelihood-ratio (LR) test, P < 0.05). c, d Same analyses as in Fig. 2a, b, but for all patients with Gleason score 7 tumors. e–f Same
analyses as in Fig. 2a, b, but for patients with Gleason score 7(3 + 4) tumors
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Gleason score, or grade of the tumor, is the best pre-
dictor of PCa prognosis in patients with localized disease
[19]. While patients diagnosed with Gleason ≤6 tumors
typically have a favorable prognosis, patients with
Gleason 8–10 tumors are most likely to experience dis-
ease recurrence and progression [19, 32]. We therefore
Table 3 Hazard ratios and 95 % confidence intervals for the association of the epigenetic signature with prostate cancer recurrence
Patients Analysis model Variables Recurrence
HR (95 % CI) P value
All
Univariate
Signature (per 25 % increase) 1.78 (1.48, 2.16) 2.05E−09
Multivariate
Signature (per 25 % increase) 1.48 (1.21, 1.81) 1.38E−04
Age (per 1-year increase) 0.98 (0.95, 1.01) 0.21
Gleason score
≤6 1.00
7(3 + 4) 2.25 (1.32, 3.48) 2.89E−03
7(4 + 3) 5.04 (2.64, 9.65) 1.02E−06
8–10 4.06 (2.00, 8.26) 1.08E−04
Pathological stagea
Local 1.00
Regional 2.04 (1.33, 3.14) 1.13E−03
Diagnostic PSA level (per 1-unit increase) 1.00 (1.00, 1.00) 0.92
Patients with Gleason 7 tumors
Univariate
Signature (per 25 % increase) 1.81 (1.42, 2.31) 1.38E−06
Multivariate
Signature (per 25 % increase) 1.59 (1.24, 2.05) 3.21E−04
Age (per 1-year increase) 0.99 (0.95, 1.03) 0.56
Gleason score
7(3 + 4) 1.00
7(4 + 3) 2.08 (1.18, 3.65) 1.09E−02
Pathological stagea
Local 1.00
Regional 1.82 (1.06, 3.11) 2.94E−02
Diagnostic PSA level (per 1-unit increase) 1.00 (0.99, 1.01) 0.82
Patients with Gleason 7(3 + 4) tumors
Univariate
Signature (per 25 % increase) 1.83 (1.36, 2.45) 5.64E−05
Multivariate
Signature (per 25 % increase) 1.65 (1.21, 2.25) 1.54E−03
Age (per 1-year increase) 1.00 (0.95, 1.05) 0.86
Pathological stagea
Local 1.00
Regional 1.83 (0.97, 3.45) 0.06
Diagnostic PSA level (per 1-unit increase) 1.00 (0.99, 1.01) 0.80
CI confidence interval, HR hazard ratio, PSA prostate-specific antigen
aLocal stage is pT2, N0/NX, M0. Regional stage is pT3-T4 and/or N1, M0
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generated a signature by contrasting patients with high
(8–10) versus low (≤6) Gleason score tumors.
Importantly, the study showed that the signature signifi-
cantly improved the prediction of recurrence in patients
diagnosed with Gleason score 7 tumors. Compared to
standard clinical-pathological parameters, the signature
improved the AUC for recurrence by 12 %; and for pa-
tients with 3 + 4 tumors, there was a 19 % increase in
AUC. Patients with Gleason score 7 tumors are clinically
heterogeneous [29, 33]. These patients have a variable
prognosis, and predicting PCa outcomes is often chal-
lenging. The methylation signature may therefore have
potential to further improve the prognostication of these
patients and might have clinical utility to help guide
clinical decision-making (e.g., adjuvant therapy) after
radical prostatectomy [34]. Further validation of the sig-
nature is however required.
The epigenetic signature, which was created using an
agnostic method, includes 52 differentially methylated
CpG sites. The genes that encompass CpGs in the signa-
ture have roles in different biological pathways including
ion channel transport, Akt signaling, and cell cycle, all of
which are important for PCa growth. Four genes in the
signature encode cell cycle-related targets of E2F tran-
scription factors (PLK1, CDC25B, MKI67, and RRM2)
[27]. The E2F pathway has a crucial role in cell cycle
proliferation and the progression of PCa [35]. We also
showed that the methylation levels of several CpGs were
associated with mRNA expression levels of the corre-
sponding genes. While the strength of the correlation
was modest for most genes, a few genes revealed stron-
ger correlations: ANO7, ARHGEF7, and PTPRN2. The
CpGs in these genes were in the gene body or 3′UTR,
and higher methylation levels in higher Gleason score
tumors were associated with lower mRNA expression of
all three genes. Although the link between methylation
in these regions of the gene and mRNA expression is
not well understood, there is evidence from previous
studies that intragenic (gene body) DNA methylation
could reduce the efficiency of transcription elongation
[36]. The role of ARHGEF7 and PTPRN2 in PCa is un-
known, but ANO7 encodes a polytopic membrane pro-
tein that is prostate-specific [37], and the methylated
CpG site in this gene might therefore be a promising
biomarker for more aggressive PCa. The gene is also be-
ing studied as a potential target for PCa immunotherapy
[38]. Further, a previous study showed that the expres-
sion of ANO7 and PTPRN2 is downregulated in meta-
static prostate tumors [39].
Gene Set Enrichment Analysis showed that the epigen-
etic signature was associated with increased expression
of genes related to cell cycle proliferation. Increased
cell proliferation is a key feature of cancer that is re-
quired for further neoplastic progression [40]. Previ-
ously, Cuzick et al. identified a 31-gene expression
score of cell cycle proliferation (CCP) for predicting
PCa outcomes [30]. The score is associated with PCa-
specific mortality when assessed in primary tumors
[30, 31]. In our study, the majority of the genes in the
CCP score (n = 25) were upregulated with higher levels
Table 4 Gene Set Enrichment Analysis results
Gene set name Description NES
Positive enrichment score
HALLMARK_E2F_TARGETS Genes encoding cell cycle-related targets of E2F transcription factors 3.86
HALLMARK_G2M_CHECKPOINT Genes involved in the G2/M checkpoint, as in progression through
the cell division cycle
3.08
HALLMARK_MITOTIC_SPINDLE Genes important for mitotic spindle assembly 2.19
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION Genes defining epithelial-mesenchymal transition, as in wound
healing, fibrosis, and metastasis
2.15
HALLMARK_ALLOGRAFT_REJECTION Genes upregulated during transplant rejection 1.96
HALLMARK_MYC_TARGETS_V1 A subgroup of genes regulated by MYC—version 1 (v1) 1.87
Negative enrichment score
HALLMARK_ANDROGEN_RESPONSE Genes defining response to androgens −2.83
HALLMARK_FATTY_ACID_METABOLISM Genes encoding proteins involved in metabolism of fatty acids −2.04
HALLMARK_XENOBIOTIC_METABOLISM Genes encoding proteins involved in processing of drugs and
other xenobiotics
−1.98
We identified genes that showed increased expression with higher levels of the epigenetic signature (FDR Q < 0.05; n = 1108) or decreased expression with higher
levels of the signature (FDR Q < 0.05; n = 1357). These genes were pre-ranked according to Pearson correlation, and this pre-ranked list was used as input for GSEA.
The gene sets in the table have an FDR Q value < 0.05. A positive value for the NES indicates that higher levels of the signature were associated with increased
expression of the genes in a gene set
FDR false discovery rate, NES normalized enrichment score
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of the epigenetic signature. In addition, GSEA showed
that the signature was associated with decreased ex-
pression of androgen-responsive genes. Androgens
regulate vital aspects of prostate growth and function
[41], and androgen receptor activity inversely corre-
lates with cell cycle proliferation in advanced PCa [42].
Therefore, the epigenetic signature seems to capture
important biological pathways and events related to
prostate tumor progression.
A number of previous studies on DNA methylation
biomarkers for predicting PCa outcomes in patients with
localized disease have been conducted. Most of these
previous investigations focused on specific candidate
genes. Evidence from these studies suggests that hyper-
methylation of PITX2, GSTP1, and APC is associated
with more aggressive PCa and disease prognosis [11, 12].
Some other prior studies have focused on larger sets of
CpG sites across the genome and identified different
panels of CpG biomarkers for distinguishing more from
less aggressive prostate tumors [13–18]. For example, in
a previous epigenome-wide analysis from our group, we
identified a panel of methylation biomarkers for predict-
ing metastatic-lethal PCa [18]. None of the differentially
methylated CpG sites in the prior studies, however, are
included in the epigenetic signature of Gleason score. It
is important to note that several of the previous studies
were limited by small sample size and a limited number
of CpG markers evaluated. Additional large investiga-
tions of DNA methylation biomarkers for PCa recur-
rence are therefore needed, including studies to further
validate our epigenetic signature and other previously
identified prognostic CpG biomarkers.
The present study has important strengths including
the relatively large number of patients and the agnos-
tic, genome-wide approach used for building the
prognostic epigenetic classifier in the TCGA discovery
dataset. The testing cohort has a prospective design
with long-term follow-up for patient outcomes. Other
prognostic tools (e.g., CAPRA-S, Decipher) were not
tested in this study, and additional comparative stud-
ies are therefore needed.
Conclusions
Better tools to identify at the time of diagnosis the sub-
set of PCa patients at the highest risk of recurrence are
urgently needed. Our study provides new evidence that
DNA methylation profiling has the clinical potential to
improve risk prediction for PCa outcomes in patients
with clinically localized disease, particularly in patients
with Gleason score 7 tumors, which have a variable
clinical course and represent a substantial proportion
of prostate cancer patients diagnosed worldwide each
year.
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